Back to Back Issues Page
Argus II - A New Way of Seeing ;Clinical Trial to Begin for Dry AMD
January 13, 2015

Argus II - Clinical Trial to Begin for Dry AMD

The Argus II is a system of high tech devices, including a miniature video camera and implanted electrodes, that work together to restore visual function in those who are blind. The device has been implanted in more than 100 individuals worldwide.

Health Canada - January 12, 2015

However, a new milestone was achieved on January 12, 2015 when it received Health Canada approval to be used in the treatment of those with severe to profound outer retinal degeneration such as retinitis pigmentosa (RP).

“This is one of the most exciting medical developments I have witnessed in my career,” said Robert Devenyi, MD, FACS, Ophthalmologist-in-Chief, Donald K. Johnson Eye Centre and Director, Retinal Services, at the University Health Network. “The Argus II offers so much hope and possibility for patients with degenerative eye disease. I am delighted to be part of the first team in Canada that can provide this technology to patients.”

FDA Approval

The system received European (CE Mark) approval in 2011 and U.S. Food and Drug Administration (FDA) approval in 2013. However, so far the device has only been used for those with RP.

Although not yet recruiting, there will soon be a clinical trial investigating the safety of the system as well as evaluating the ability of it to restore vision in those with advanced dry AMD.

Find out how the Argus II works, it's future for dry AMD, and how it impacted the life of a patient who was treated by Duke University:

Argus II

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page